SA521430793B1 - أجسام مضادة مضادة لسيما 3أ واستخداماتها في علاج أمراض العين أو البصر - Google Patents
أجسام مضادة مضادة لسيما 3أ واستخداماتها في علاج أمراض العين أو البصرInfo
- Publication number
- SA521430793B1 SA521430793B1 SA521430793A SA521430793A SA521430793B1 SA 521430793 B1 SA521430793 B1 SA 521430793B1 SA 521430793 A SA521430793 A SA 521430793A SA 521430793 A SA521430793 A SA 521430793A SA 521430793 B1 SA521430793 B1 SA 521430793B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- ocular diseases
- treating eye
- sema3a
- antibodies
- sema3a antibodies
- Prior art date
Links
- 208000022873 Ocular disease Diseases 0.000 title 1
- 208000030533 eye disease Diseases 0.000 title 1
- 102000013008 Semaphorin-3A Human genes 0.000 abstract 2
- 108010090319 Semaphorin-3A Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19173454 | 2019-05-09 | ||
| PCT/EP2020/062802 WO2020225400A1 (en) | 2019-05-09 | 2020-05-08 | Anti-sema3a antibodies and their uses for treating eye or ocular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA521430793B1 true SA521430793B1 (ar) | 2024-03-28 |
Family
ID=66476463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA521430793A SA521430793B1 (ar) | 2019-05-09 | 2021-11-09 | أجسام مضادة مضادة لسيما 3أ واستخداماتها في علاج أمراض العين أو البصر |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US11267880B2 (enExample) |
| EP (1) | EP3966239A1 (enExample) |
| JP (2) | JP7314310B2 (enExample) |
| KR (1) | KR20220007128A (enExample) |
| CN (1) | CN113795509A (enExample) |
| AR (1) | AR122266A1 (enExample) |
| AU (1) | AU2020267874A1 (enExample) |
| BR (1) | BR112021019854A2 (enExample) |
| CA (1) | CA3137377A1 (enExample) |
| CL (1) | CL2021002795A1 (enExample) |
| CO (1) | CO2021014768A2 (enExample) |
| CR (1) | CR20210559A (enExample) |
| DO (1) | DOP2021000226A (enExample) |
| EA (1) | EA202193038A1 (enExample) |
| EC (1) | ECSP21082527A (enExample) |
| IL (1) | IL287758A (enExample) |
| JO (1) | JOP20210300A1 (enExample) |
| MA (1) | MA55872A (enExample) |
| MX (1) | MX2021013671A (enExample) |
| MY (1) | MY206253A (enExample) |
| NZ (1) | NZ780763A (enExample) |
| PE (1) | PE20220287A1 (enExample) |
| PH (1) | PH12021552776A1 (enExample) |
| SA (1) | SA521430793B1 (enExample) |
| SG (1) | SG11202110842QA (enExample) |
| TW (1) | TWI836069B (enExample) |
| UA (1) | UA129953C2 (enExample) |
| WO (1) | WO2020225400A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR122266A1 (es) | 2019-05-09 | 2022-08-31 | Boehringer Ingelheim Int | Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares |
| US20220127344A1 (en) * | 2020-10-23 | 2022-04-28 | Boehringer Ingelheim International Gmbh | Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina |
| EP4314047A1 (en) * | 2021-03-30 | 2024-02-07 | Bayer Aktiengesellschaft | Anti-sema3a antibodies and uses thereof |
| CN116790610B (zh) * | 2023-05-18 | 2024-09-20 | 四川大学 | 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| EP1005870B1 (en) | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| JP5888728B2 (ja) * | 2009-11-05 | 2016-03-22 | 国立大学法人大阪大学 | 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法 |
| WO2013005603A1 (ja) * | 2011-07-01 | 2013-01-10 | 公立大学法人横浜市立大学 | 結膜におけるアレルギー性炎症の予防及び／又は治療剤 |
| US9879075B2 (en) | 2013-02-06 | 2018-01-30 | Yokohama City University and Chiome Bioscience Inc. | Anti-semaphorin 3A antibody and treatment of Alzheimer's disease and inflammatory immune diseases using same |
| EP2958580B1 (en) * | 2013-02-21 | 2025-12-10 | RSEM, Limited Partnership | Inhibition of sema3a in the prevention and treatment of ocular hyperpermeability |
| CA2960054C (en) * | 2014-09-05 | 2023-11-14 | Rsem, Limited Partnership | Compositions and methods for treating and preventing inflammation |
| WO2017074013A1 (ko) | 2015-10-27 | 2017-05-04 | 사회복지법인 삼성생명공익재단 | 인간 및 마우스 sema3a에 교차결합하는 항체 및 그의 용도 |
| KR101854529B1 (ko) * | 2015-10-27 | 2018-05-04 | (주) 팬젠 | 인간 및 마우스 Ｓｅｍａ３Ａ에 교차결합하는 항체 및 그의 용도 |
| US10604571B2 (en) | 2015-10-27 | 2020-03-31 | Samsung Life Public Welfare Foundation | Antibody to human and mouse SEMA3A and use thereof |
| AR122266A1 (es) * | 2019-05-09 | 2022-08-31 | Boehringer Ingelheim Int | Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares |
-
2020
- 2020-05-08 AR ARP200101337A patent/AR122266A1/es unknown
- 2020-05-08 AU AU2020267874A patent/AU2020267874A1/en active Pending
- 2020-05-08 US US16/869,618 patent/US11267880B2/en active Active
- 2020-05-08 MX MX2021013671A patent/MX2021013671A/es unknown
- 2020-05-08 CA CA3137377A patent/CA3137377A1/en active Pending
- 2020-05-08 JP JP2021565942A patent/JP7314310B2/ja active Active
- 2020-05-08 PH PH1/2021/552776A patent/PH12021552776A1/en unknown
- 2020-05-08 CR CR20210559A patent/CR20210559A/es unknown
- 2020-05-08 MA MA055872A patent/MA55872A/fr unknown
- 2020-05-08 CN CN202080034499.1A patent/CN113795509A/zh active Pending
- 2020-05-08 PE PE2021001846A patent/PE20220287A1/es unknown
- 2020-05-08 JO JOP/2021/0300A patent/JOP20210300A1/ar unknown
- 2020-05-08 TW TW109115394A patent/TWI836069B/zh active
- 2020-05-08 EA EA202193038A patent/EA202193038A1/ru unknown
- 2020-05-08 SG SG11202110842QA patent/SG11202110842QA/en unknown
- 2020-05-08 UA UAA202106857A patent/UA129953C2/uk unknown
- 2020-05-08 WO PCT/EP2020/062802 patent/WO2020225400A1/en not_active Ceased
- 2020-05-08 BR BR112021019854A patent/BR112021019854A2/pt active Search and Examination
- 2020-05-08 NZ NZ780763A patent/NZ780763A/en unknown
- 2020-05-08 EP EP20723153.1A patent/EP3966239A1/en active Pending
- 2020-05-08 KR KR1020217040292A patent/KR20220007128A/ko active Pending
- 2020-05-08 MY MYPI2021005850A patent/MY206253A/en unknown
-
2021
- 2021-10-25 CL CL2021002795A patent/CL2021002795A1/es unknown
- 2021-11-01 IL IL287758A patent/IL287758A/en unknown
- 2021-11-01 DO DO2021000226A patent/DOP2021000226A/es unknown
- 2021-11-02 CO CONC2021/0014768A patent/CO2021014768A2/es unknown
- 2021-11-09 SA SA521430793A patent/SA521430793B1/ar unknown
- 2021-11-18 EC ECSENADI202182527A patent/ECSP21082527A/es unknown
-
2022
- 2022-01-25 US US17/583,245 patent/US20220144929A1/en not_active Abandoned
-
2023
- 2023-07-12 JP JP2023114243A patent/JP7638332B2/ja active Active
-
2024
- 2024-01-26 US US18/423,352 patent/US20240336674A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA521430793B1 (ar) | أجسام مضادة مضادة لسيما 3أ واستخداماتها في علاج أمراض العين أو البصر | |
| CR20220626A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf | |
| AU2018338314A1 (en) | Protein degraders and uses thereof | |
| MY207784A (en) | Anti-cd73 antibodies | |
| EP4183806A3 (en) | Glycan-interacting compounds and methods of use | |
| EA201992143A1 (ru) | Биспецифические антитела, перенаправляющие т-клетки, для лечения egfr-положительных раковых заболеваний | |
| WO2020209988A3 (en) | Diverse marker panel for ptsd diagnosis and treatment | |
| MX2023005591A (es) | Metodos de tratamiento de enfermedades y trastornos. | |
| ZA201907371B (en) | Methods and compositions for treating allergic ocular diseases | |
| EA202092593A1 (ru) | Белки, связывающие каннабиноидный рецептор 1-го типа (cb1), и их применение | |
| CR20240265A (es) | Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares | |
| PH12022551377A1 (en) | Vegf mini-traps and method of use thereof | |
| MX2021010766A (es) | Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos. | |
| PH12022550277A1 (en) | Biopharmacuetical compositions and related methods | |
| NZ750976A (en) | Anti-gm-csf antibodies and uses thereof | |
| MX2020012011A (es) | Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. | |
| PH12022550619A1 (en) | Anti-nrpia antibodies and their uses for treating eye or ocular diseases | |
| WO2020186111A3 (en) | Vista-binding antibodies and uses thereof | |
| MX2023004643A (es) | Anticuerpos anti-sema3a y sus usos para tratar una enfermedad trombotica de la retina. | |
| EA202092123A1 (ru) | Антитела против клаудина 18.2 и их применения | |
| HK40077248A (en) | Anti-nrp1a antibodies and their uses for treating eye or ocular diseases | |
| HK40066503A (en) | Anti-sema3a antibodies and their uses for treating eye or ocular diseases | |
| IL283497A (en) | Methods, preparations and kits for the treatment of eye diseases | |
| MX2022008391A (es) | Anticuerpos epiteliales específicos de cadherina. | |
| HK40062990A (en) | Methods, compositions, and kits for treating ocular diseases |